EMPE Diagnostics

Globally, 10 million new cases every year and 4000 people die every day due to Tuberculosis (TB). TB is curable if detected at early stages and treated with correct antibiotics. If not, the TB bacteria develops resistance and becomes a challenge for diagnosis and treatment. Rapid and accurate detection of multi-drug resistant (MDR) strains is urgently needed to effectively treat patients and prevent spreading of drug-resistant TB in the community. EMPE Diagnostics AB, Sweden has developed mfloDx technology that can rapidly detect the TB causing bacteria and its drug-resistance profiles in less than 3 hours, directly from patients sputum samples....

In vitro diagnostics,infectious diseases,tuberculosis,biotechnology,sexually transmitted diseases,lateral flow technology,padlock probe and rolling circle amplification,and drug resistance

Empe diagnostics operates in the Medical device industry.

Empe diagnostics's revenue is 11m - 100m

Empe diagnostics has 11 - 50 employees.